title: Opioid adjuvant strategy: improving opioid effectiveness.
abstract: Opioid analgesics continue to be the mainstay of pharmacologic treatment of moderate to severe pain. Many patients, particularly those suffering from chronic pain, require chronic high-dose analgesic therapy. Achieving clinical efficacy and tolerability of such treatment regimens is hampered by the appearance of opioid-induced side effects such as tolerance, hyperalgesia and withdrawal syndrome. Among the therapeutic options to improve the opioid effectiveness, this current review focuses on strategies combining opioids to other drugs that can modulate opioid-mediated effects. We will discuss about experimental evidences reported for several potential opioid adjuvants, including N-methyl-D-aspartate receptor antagonists, 5-HT7 agonists, sigma-1 antagonists, I2-R ligands, cholecystokinin antagonists, neuropeptide FF-R antagonists and toll-like receptor 4 antagonists.
authors.affiliation: Faculty of Pharmacy, University of Strasbourg, CNRS, UMR7200, 67400 Illkirch Graffenstaden, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Bihel
mesh_terms: D000701:Analgesics, Opioid / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D000701:Analgesics, Opioid
keywords: 5-HT7; CCK; NMDA; NPFF; TLR4; adjuvant; imidazoline I2; opioid; sigma-1